The University of Melbourne

Morphosys Ag

John Allan Hamilton

Andrew David Cook

Ian Keith Campbell

Prudence H Hart

Stefan Steidl

Adrian Achuthan

Derek Lacey

Gary Peter Anderson

The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA) and/or pain. In accordance with the present invention, an antagonist of c-Fms is effective in the treatment of osteoarthritis and/or pain. An antagonist of M-CSF includes, but is not limited to, an antibody that is specific for M-CSF, IL-34 or c-Fms.

Method for treatment of osteoarthritis with C-Fms antagonists

A protocol for pain management includes a pharmaceutical composition and its use in ameliorating the sensation of pain. The protocol includes the use of a CCL17 signaling antagonist alone or in combination with another analgesic compound to treat pain associated with inflammatory conditions. The CCL17 signaling antagonist includes an antibody or antigen-binding derivative thereof which binds to CCL17 or its receptor.

Method of treatment of pain by administration of a CCL17 specific antibody

The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.

Pain treatment

Methods of treating pain using an antibody specific for GM-CSF

The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (OA). In accordance with the present invention, an antagonist of GM-CSF can be effective in the treatment of osteoarthritis. An antagonist of GM-CSF includes, but is not limited to, an antibody that is specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models.

Osteoarthritis treatment

Use of M-CSF antibodies in the treatment of osteoarthritis or pain

Method of treating pain using an antagonist of GM-CSF

The present invention relates generally to a method for the treatment and prophylaxis of inflammatory conditions. The present invention is predicated in part on the identification of cells of the monocyte/macrophage lineage being critical for inflammation and, in particular, chronic inflammation. In accordance with the present invention, it is proposed that the reduction in levels of monocyte/macrophage-type cells and/or a reduction in the production of inflammatory and pro-inflammatory mediators by these cells, especially locally, is effective in reducing inflammatory conditions. The present invention further provides animal models useful for screening for reducing levels of monocyte/macrophage-type cells and/or reducing the production of inflammatory and pro-inflammatory mediators of these cells.

Method of treating rheumatoid arthritis with antibodies to M-CSF

Methods of ameliorating inflammatory disease using an uPA antagonist

Method of treatment and agents useful for same

Therapeutic compositions and methods for the treatment of inflammation are disclosed. The compositions comprise at least one anti-inflammatory drug in combination with the lymphokine interleukin-4 (IL-4), which components interact synergistically in the treatmement of inflammation. Methods for the treatment of inflammation comprise administering to a subject in need of such treatment an effective amount of at least one anti-inflammatory drug and IL-4.

Growing community of inventors

Aberfeldie, Australia

John Allan Hamilton